SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Inrebic

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approval August 16, 2019; European Commission approval February 2021).
Why 3/10
Inrebic is already FDA-approved and marketed with no pending PDUFA date or pivotal readout in the next ~12 months. The Phase 2 MDS/MPN data at ASCO 2026 was an investigator-initiated study, not a BMS-sponsored registrational trial, and no sNDA has been announced. As a minor product within BMY's massive portfolio, even a label expansion would not be a company-defining binary event.
Actionable Insight NEUTRAL

Inrebic is an already-approved, marketed drug with no upcoming PDUFA or pivotal readout. The next potential catalyst to watch is whether BMS pursues a label expansion into MDS/MPN overlap syndromes based on the Phase 2 data presented at ASCO 2026, but no sNDA filing has been announced. For a company the size of BMY ($48B+ annual revenue), Inrebic is a minor product whose sales are not even broken out separately, so even a label expansion would be a modest contributor.

Price Chart

Loading chart...

Executive Summary

Inrebic (fedratinib) is an oral JAK2 inhibitor approved by the FDA in August 2019 for adults with intermediate-2 or high-risk myelofibrosis, a rare bone marrow cancer. It was originally developed by Celgene and is now owned by Bristol Myers Squibb (BMY), which acquired Celgene in late 2019. Inrebic was the first new myelofibrosis treatment in nearly a decade, offering an option for patients who cannot tolerate or have failed Incyte's market-leading Jakafi (ruxolitinib). However, Inrebic is a minor product for BMY: the company does not break out its revenue separately, and it is grouped with other small brands in BMY's "Growth Portfolio." The drug faces entrenched competition from ruxolitinib and newer JAK inhibitors. A Phase 2 study presented at ASCO 2026 showed promise in MDS/MPN overlap syndromes, but no registrational trial or sNDA has been announced. With no upcoming binary catalysts, Inrebic is a steady but unexciting contributor to BMY's diversified portfolio.

How It Works

Inrebic (fedratinib) is an oral capsule that blocks an enzyme called JAK2, which is overactive in myelofibrosis, a rare bone marrow cancer. By inhibiting JAK2, the drug disrupts abnormal signaling that causes the bone marrow to produce too many blood cells and leads to an enlarged spleen and other symptoms. It also blocks a related enzyme called FLT3.

Trial Status

Inrebic is FDA-approved for myelofibrosis based on the Phase 3 JAKARTA trial (NCT01437787), which showed approximately 37% of patients receiving 400 mg fedratinib achieved a 35% or greater reduction in spleen volume at 24 weeks. The drug is also approved in Europe. A Phase 2 investigator-initiated study (NCT05177211) presented at ASCO 2026 showed clinical benefit in MDS/MPN overlap syndromes and chronic neutrophilic leukemia. A Phase 2 study combining fedratinib with nivolumab (FRACTION trial) was presented at EHA 2026. An active Phase 2 study (NCT04817007) is evaluating BMS-986158 (a BET inhibitor) in combination with fedratinib or ruxolitinib in myelofibrosis.

The Two-Sided Case

▲ Bull Case4
Inrebic was the first new FDA-approved treatment for myelofibrosis in nearly a decade (approved August 2019), offering a differentiated oral JAK2-selective option for patients who are intolerant of or progress on ruxolitinib.
Phase 2 data presented at ASCO 2026 showed fedratinib produced clinical benefit in MDS/MPN overlap syndromes and chronic neutrophilic leukemia, suggesting potential for label expansion into additional rare blood cancer indications.
Patent protection extends to approximately 2039, providing a long runway of market exclusivity with no near-term generic threat.
The global fedratinib market was estimated at roughly $501.5 million in 2024 and is projected to grow at a CAGR of ~9-10%, driven by increasing diagnosis and targeted therapy adoption in myelofibrosis.
▼ Bear Case4
Inrebic is a minor product for BMY: the company does not break out its revenue separately in SEC filings, signaling it is immaterial to the overall $48B+ annual revenue base.
The myelofibrosis market is dominated by Incyte's Jakafi (ruxolitinib), which has a strong first-mover advantage and multiple approved indications. Inrebic also faces competition from newer JAK inhibitors like pacritinib and momelotinib.
Inrebic carries a boxed warning for serious gastrointestinal toxicity, including diarrhea, nausea and vomiting, which can limit its tolerability and adoption.
The drug was originally developed by Celgene and acquired via the $74B Celgene merger; it was never a pipeline priority for BMS and has seen limited commercial investment.

Upcoming Catalysts

  • No upcoming PDUFA dates or pivotal readouts identified. Potential future catalyst: BMS may pursue an sNDA for MDS/MPN overlap syndromes if Phase 2 data supports a registrational path, but no filing has been announced.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 13

Hover a chip for the title
1 en.wikipedia.org2 drugpatentwatch.com3 drugs.com4 biocosm.io5 cognitivemarketresearch.com6 ascopubs.org7 cancernetwork.com8 assyro.com9 news.bms.com10 stockanalysis.com11 pharsight.greyb.com12 eureka.patsnap.com13 sec.gov